Investors in Science

The Merantix AI Fund builds and invests in category-defining early-stage AI-native companies, always seeking the largest exponential lever through AI as a general-purpose technology. We strongly believe in and focus on vertically integrated business models, data flywheel effects, multidisciplinary founding teams, societal impact, and leveraging the European industry sovereignty.

We complement our own research and development capabilities with those of external researchers, startups and other partners to bring innovative products and services to market more quickly. As part of our open innovation approach, we also invest into startup companies and organizations through venture capital (VC). We have a long track record of leveraging VC investing to help us to stay on top of the latest food industry trends. Today, we focus on three investment pillars - health science, innovation and sustainability - to drive new business and support our path to Net Zero, with businesses and technologies that can be deployed across our value chain. Through VC funding, we provide catalytic capital to support pioneering ideas on their launch and growth journey. Our investment strategy is predominantly based on a fund of funds approach, where we invest in VC funds with a proven track record and industry expertise.

SINTEF has developed venture funds, the latest of which is called SINTEF Venture VI Fund. It will manage a capital of some €50 million, of which EIF is investing some €20 million. This substantial investment aims to promote the creation of 10-15 new companies, leveraging SINTEF’s tradition of pioneering technological innovations. The EIF also invested in SINTEF’s previous funds – EIF invested €10 million in 2014 and increased to €15 million in 2018. Fund’s latest investments: Cartesian AS – Offers heating and cooling solutions by storing and extracting thermal energy from phase change materials. MoreScope – Provides a data-driven platform for companies and investors to use to quantify climate impact, carbon footprint and avoided emissions. Sonair – Offers a 3D ultrasonic sensor for robots. Mia Health – Offers a solution that gives individuals and companies easy and precise insight into the actual health benefits of the activity in which they are involved.

Digital healthcare, innovations and environmental health.

*Community based training program and team traing program focusing priorities on protection is better than cure. Digital health, healthcare and laboratory research programs. *Environmental health Protection. *Innovations and AI.

Global VC firm focusing on science and technology-based, positive-impact, startups.

Research center in nanoelectronics. Imec is a world-leading R&D and innovation hub in nanoelectronics and digital technologies. At times, we shape the future. Founded in 1984, imec quickly made its name as the leading research hub for advanced CMOS scaling. We will continue to shape the roadmap for the semiconductor industry for years to come.

Valide.no supports researchers and entrepreneurs in commercializing innovative solutions with expertise, networking, and capital, contributing to a better world through research-based products and ideas

Birk Venture is a company based in Oslo, Norway, dedicated to transforming unique innovations and technologies into successful businesses in the healthcare sector. They focus on leveraging cutting-edge technologies in life science to meet the increasin.

Columbus is a Spanish investment management company that focuses on generating high returns through the Columbus Innvierte Life Science fund. This fund targets seed-stage investments in established private companies within the healthcare and life sciences sectors. The company boasts a robust investment team with international experience and a proven track record in identifying innovative excellence originating from Spanish academic institutions. COLUMBUS VENTURE PARTNERS, SGEIC, SA leverages its expertise in company building and financing to accelerate commercialization for its portfolio companies. Additionally, it facilitates rapid access to the vibrant UK and Boston/Cambridge biotech/pharma venture capital R&D ecosystem.

Invivo Partners, founded by Albert Ferrer and Luis Pareras, is a management company specializing in early-stage investments in the healthcare sector. They leverage a team of highly skilled professionals with expertise in scientific, technical, and financial analysis, supported by a strong network within the health ecosystem. Managed under Invivo Partners, Invivo Ventures operates based on the success of their initial fund, Healthequity, which closed at 60 million euros after registration with CNMV in 2019. Backed by prominent institutions and private investors, Invivo Partners has achieved notable exits and significant funding for their portfolio companies, emphasizing groundbreaking scientific innovations. Their strategic insights into Technology Transfer and ability to identify emerging trends position them as a leading player in Europe's Technology Transfer landscape.

Asabys Partners is a venture capital firm based in Barcelona that invests broadly in human healthcare. The firm is active in the health-tech and biopharma industries, targeting investments in Spain and internationally in highly innovative and transformative technologies. Motivated by the goal of pushing the boundaries of science and medicine, Asabys Partners sources and finances the most disruptive technologies and collaborates with top internal and external talents in the industry. With an entrepreneurial spirit, the firm seeks to be involved in the building and management of its companies, considering itself not just as investors, but as partners and collaborators to its portfolio companies.